Clinical Trial

Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label phase Ib/IIa clinical study conducted in China, aimed at evaluating the safety tolerance, efficacy, pharmacokinetic (PK) characteristics, and immunogenicity of DR30206 in combination with standard treatment regimens for advanced or metastatic gastrointestinal tumors.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-04-30 -> 2027-04-30 2026-07-01
minor Completion pushed: 2026-06-30 -> 2027-06-30 2026-07-01
Trial Details
NCT Number NCT07056777
Lead Sponsor Zhejiang Doer Biologics Co., Ltd.
Conditions Gastrointestinal Cancer
Enrollment 186 participants
Start Date 2025-03-25
Primary Completion 2027-04-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-30